NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Neumora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.47−0.00 (-0.80%)
Close on Oct 19, 2026
- Market cap
- $87.03M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -121.2% | |
| Return on assets | – | – | -93.3% | |
| Current ratio | – | – | 5.87 | |
| Debt to equity | – | – | 1.10 | |
| Net debt to EBITDA | – | – | 0.28× | |
| Diluted shares | – | – | 163M |
Cash use needs five years of cash flow figures
Neumora Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$236.93M
- Cash generatingOperating cash flow above zero-$206.44M
- Return on assets improvedROA up on the prior year-49.1% → -74.7%
- Earnings backed by cashOperating cash flow above net income-$206.44M vs -$236.93M
- Less leverageLong-term debt to assets fell0.0% → 28.5%
- Better liquidityCurrent ratio rose10.51 → 5.87
- No dilutionShare count did not rise159M → 163M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –